Subject of the day
1SXP.DE
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
| Line | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|
| Revenue | $252.33M | $256.46M | $247.58M | $240.19M |
| Gross profit | $83.72M | $96.10M | $76.08M | $79.75M |
| Operating income | $49.69M | $60.12M | $41.37M | $39.05M |
| Net income | $38.44M | $45.56M | $33.55M | $33.18M |
| Diluted EPS | 0.26 | 0.30 | — | 0.22 |
| Free cash flow | $17.45M | $16.89M | -$3.12M | -$20.04M |
| CapEx | -$29.88M | -$38.29M | -$55.46M | -$23.44M |
$21.80
▲ +0.50 (+2.3%)
| 52w hi | $23.50 |
|---|---|
| 52w lo | $12.96 |
| Vol | 128.13K |
| As of | Aug 13 |
Our score +0.36
| Short | +0.47 |
|---|---|
| Medium | +0.34 |
| Long | +0.17 |
computed 2026-08-13
SCHOTT Pharma AG & Co. KGaA
Healthcare · Medical Instruments & Supplies
| Market cap | $3.28B |
|---|---|
| Enterprise value | $3.46B |
| Trailing P/E | 22.95x |
| Forward P/E | 20.30x |
| EV / EBITDA | 14.04x |
| P / S (ttm) | 3.23x |
| Profit margin | 13.4% |
| Return on equity | 14.7% |
| Revenue growth | +9.9% |
| Earnings growth | -13.3% |
| Debt / equity | 23.17 |
| Beta vs SPX | 0.39 |
|---|---|
| Corr SPX | 0.17 |
| Annual vol | 37.4% |
| Annual ret | -14.3% |
| Sharpe | -0.38 |
| Max DD | -64.8% |
Window: 504 trading days (489 obs)
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.18 | |
| Sector | +0.12 | |
| Technical | +0.00 | |
| Earnings | +0.00 | |
| Sentiment | +0.64 |
macro × 1.00 · 2026-08-13
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Aug 13 | $21.30 | $22.20 | $21.05 | $21.80 | 128.13K |
| Aug 12 | $22.95 | $22.95 | $20.60 | $21.30 | 185.94K |
| Aug 11 | $22.20 | $22.50 | $22.05 | $22.40 | 39.62K |
| Aug 10 | $22.60 | $22.60 | $22.05 | $22.30 | 79.92K |
| Aug 7 | $22.25 | $22.70 | $22.25 | $22.50 | 49.10K |